Plasma Services Group provides sera and other samples for materials of control reagents and calibrators for a variety of diseases.

The approach could enable 30-minute testing for a heart condition that is newly treatable following recent drug approvals.

NEW YORK – Qiagen announced on Wednesday that it has launched a third-party partnering program for its clinical digital PCR platform and signed an agreement with the program's inaugural partner, South ...

NEW YORK – The US Department of Justice said Wednesday that a Chicago lab owner has been sentenced to seven years in prison for his role in a COVID-19 testing fraud. During 2021 and 2022, lab owner ...

NEW YORK – In a letter to customers on Wednesday, Bio-Rad Laboratories announced that it has decided against implementing a tariff surcharge that the company on May 21 said it was considering for at ...

NEW YORK — EDX Medical Group said Monday that it has a signed a memorandum of understanding with UK-based healthcare group Spire Healthcare around diagnostic products and testing services. Spire ...

Adding the firm's multi-cancer early detection test to standard-of-care screening demonstrated substantially greater additional cancer detection than in Pathfinder.

The company uses artificial intelligence to detect metabolic patterns from urine samples that indicate prostate cancer.

The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.

Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.